Document:

Exhibit 4.1

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)
AN OPINION OF COUNSEL OF THE HOLDER, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD
PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA
FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

	 	Right
to Purchase1______ shares of Common Stock of Brain Scientific, Inc. (subject to adjustment as provided herein)

 

COMMON STOCK PURCHASE WARRANT

 

	No.: PPW-___ 	Issue Date:

 

BRAIN SCIENTIFIC, INC., a corporation organized
under the laws of the State of Nevada (the “Company”), hereby certifies that, for value received, ________________,
with an address at _______________________, or its assigns (the “Holder”), is entitled, subject to the terms set forth
below, to purchase from the Company at any time from the Issue Date until 5:00 p.m. E.D.T. on the [fourth] anniversary of the Issue Date
(the “Expiration Date”), up to ________2 fully paid and non-assessable shares of the Company’s common
stock, par value $0.001 per share (the “Common Stock”) at a per share purchase price equal to the Exercise Price. The aforedescribed
purchase price per share, as adjusted from time to time as herein provided, is referred to herein as the “Purchase Price.”
The number of such shares of Common Stock and the Purchase Price are subject to adjustment as provided herein. The Company may reduce
the Purchase Price for some or all of the Warrants, temporarily or permanently, provided such reduction is made as to all outstanding
Warrants. This warrant (this “Warrant”) is one of a series of substantially similar Warrants issued by the Company
together with its 10% convertible promissory notes to the Holder and other purchasers of such securities in a private placement pursuant
to the Securities Purchase Agreement between the Company and purchasers therein including the Holder (the “Purchase Agreement”).
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement. In the event that
an aggregate Purchase Price equal to $5,000,000 shall not have been sold in accordance with the terms of the Purchase Agreement by September
__, 2021, this Warrant shall be cancelled.

 

As used herein the following
terms, unless the context otherwise requires, have the following respective meanings:

 

(a) The term “Company”
shall mean Brain Scientific, Inc., a Nevada corporation.

 

(b) The term “Common
Stock” includes (i) the Company’s Common Stock, $0.001 par value per share and (ii) any Other Securities into which or
for which any of the securities described in (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization,
merger, sale of assets or otherwise.

 

 

		1	Insert number of shares determined in accordance with Section
1(c) of the Purchase Agreement

		2	Insert number of shares determined in accordance with Section
1(c) of the Purchase Agreement

 

     

    

    

 

(c) The term “Exercise
Price” shall mean3.

 

(d) The term “Other
Securities” refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate
or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise of the
Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in exchange for or
in replacement of Common Stock or Other Securities pursuant to Section 5 hereof or otherwise.

 

(e) The term “Trading
Day” shall mean any day that shares of Common Stock are traded on the Trading Market.

 

(f) The term “Trading
Market” shall mean the principal securities exchange or trading market where the Common Stock is listed or traded, including
but not limited to any tier of the OTC Markets, any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the New York Stock
Exchange, or the NYSE American, or any successor to such markets.

 

(g) [The term “VWAP”
means, for any Trading Day, the price determined by the first of the following clauses that applies: (i) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such Trading Day (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (iii) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets”
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent
bid price per share of the Common Stock so reported, or (iv) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected by mutual agreement of the Company and the holders owning no less than 50.1% of the then Warrants
outstanding.]4

 

(h) The term “Warrant
Shares” shall mean the Common Stock issuable upon exercise of this Warrant.

  

1. Exercise of Warrant.

 

1.1. Number of Shares Issuable
upon Exercise. From and after the Issue Date through and including the Expiration Date, the Holder shall be entitled to receive, upon
exercise of this Warrant in whole in accordance with the terms of Section 1.2 hereof or upon exercise of this Warrant in part in
accordance with Section 1.3 hereof, shares of Common Stock of the Company, subject to adjustment pursuant to Section 3 hereof.

 

1.2. Full Exercise. This
Warrant may be exercised in full by the Holder hereof by delivery to the Company of an original or facsimile copy of the Form of Exercise
attached as Exhibit A hereto (the “Exercise Form”) duly executed by such Holder and delivered within two (2)
business days thereafter of payment, in cash, wire transfer or by certified or official bank check payable to the order of the Company,
in the amount obtained by multiplying the number of shares of Common Stock for which this Warrant is then exercisable by the Purchase
Price then in effect. The original Warrant is not required to be surrendered to the Company until it has been fully exercised.

 

 

		3	If this warrant has been issued upon the listing of the Company’s
Common Stock on NASDAQ (the “Uplist”), insert as the Exercise Price an actual price equal to the greater of (A) $0.20, and
(B) one hundred twenty percent (120%) of closing price for the Common Stock on the Trading Day prior to the date of the Uplist. If this
warrant has been issued otherwise than upon the occasion of an Uplist, then insert the following bracketed language as the Exercise Price
[the lesser of (A) $1.08, and (B) and the greater of (x) $0.24 and (y) one hundred twenty percent (120%) of the average VWAP for the
Common Stock over the five (5) consecutive Trading Days immediately preceding the exercise date of this Warrant.]

		4	If this warrant is issued upon the occurrence of the Uplist, then
delete this definition of VWAP since it will not be necessary. If this warrant issued otherwise then upon the occasion of an Uplist remove
brackets around the definition of VWAP.

 

    2

    

    

 

1.3. Partial Exercise.
This Warrant may be exercised in part (but not for a fractional share) by delivery of a Exercise Form in the manner and at the place provided
in Section 1.2 hereof, except that the amount payable by the Holder on such partial exercise shall be the amount obtained by multiplying
(a) the number of whole shares of Common Stock designated by the Holder in the Exercise Form by (b) the Purchase Price then in effect.
On any such partial exercise, upon the written request of the Holder, provided the Holder has surrendered the original Warrant, the Company,
at its expense, will forthwith issue and deliver to or upon the order of the Holder a new Warrant of like tenor, in the name of the Holder
hereof or as such Holder (upon payment by such Holder of any applicable transfer taxes) may request, the whole number of shares of Common
Stock for which such Warrant may still be exercised.

  

1.4. Reserved

 

1.5. Company Acknowledgment.
The Company will, at the time of the exercise of the Warrant, upon the request of the Holder hereof, acknowledge in writing its continuing
obligation to afford to such Holder any rights to which such Holder shall continue to be entitled after such exercise in accordance with
the provisions of this Warrant. If the Holder shall fail to make any such request, such failure shall not affect the continuing obligation
of the Company to afford to such Holder any such rights.

 

1.6. Delivery of Stock Certificates,
etc. on Exercise. The Company agrees that, provided the purchase price listed in the Exercise Form is received as specified in Section
2 hereof, the shares of Common Stock purchased upon exercise of this Warrant shall be deemed to be issued to the Holder hereof as
the record owner of such shares as of the close of business on the date on which delivery of a Exercise Form shall have occurred and payment
made for such shares as aforesaid. As soon as practicable after the exercise of this Warrant in full or in part and the payment is made,
and in any event within five (5) business days thereafter (“Warrant Share Delivery Date”), the Company, at its expense
(including the payment by it of any applicable issue taxes), will cause to be issued in the name of, and delivered to, the Holder hereof,
or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable securities laws,
a certificate or certificates for the number of duly and validly issued, fully paid and non-assessable shares of Common Stock to which
such Holder shall be entitled on such exercise, plus, in lieu of any fractional share to which such Holder would otherwise be entitled,
cash equal to such fraction multiplied by the then Purchase Price of one full share of Common Stock, together with any other stock or
other securities and property (including cash, where applicable) to which such Holder is entitled upon such exercise pursuant to Section
1 hereof or otherwise.

 

2. Payment of Purchase
Price; Cashless Exercise.

 

(a) Payment upon exercise may
be made at the written option of the Holder either in (i) cash, wire transfer or by certified or official bank check payable to the order
of the Company equal to the applicable aggregate Purchase Price, (ii) by delivery of Common Stock issuable upon exercise of the Warrants
in accordance with Section (b) below or (iii) by a combination of any of the foregoing methods, in each case accompanied by delivery of
a properly endorsed Exercise Form, for the number of Common Stock specified in such form (as such exercise number shall be adjusted to
reflect any adjustment in the total number of shares of Common Stock issuable to the Holder per the terms of this Warrant) and the Holder
shall thereupon be entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable shares of Common Stock
determined as provided herein. Notwithstanding the immediately preceding sentence, payment upon exercise may be made in the manner described
in Section 2(b) below only with respect to Warrant Shares not included for unrestricted public resale in an effective registration
statement on the date notice of exercise is given by the Holder.

 

(b) In lieu of exercising this
Warrant for cash, the Holder, may elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof
being cancelled) by delivery of a properly endorsed Exercise Form delivered to the Company by any means described in Section 13
hereof, in which event the Company shall issue to the holder the “Net Number” of shares of Common Stock computed using the
following formula:

 

Net Number = A - (A x B)

 

For purposes of the foregoing formula:

 

A = the total number of shares with respect to
which this Warrant is then being exercised.

 

B = Purchase Price (as adjusted for stock splits, stock dividends,
stock combinations, recapitalizations, and similar events)

    3

    

    

 

For purposes of Rule 144 promulgated
under the 1933 Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless exercise transaction in the
manner described above shall be deemed to have been acquired by the Holder, and the holding period for the underlying shares of Common
Stock shall be deemed to have commenced, on the date this Warrant was originally issued.

  

3. Adjustment for Reorganization,
Consolidation, Merger, etc..

 

3.1. Continuation of Terms.
Upon any reorganization, consolidation, merger or transfer (and any dissolution following any transfer) referred to in this Section
3 hereof, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the Other Securities and
property receivable on the exercise of this Warrant after the consummation of such reorganization, consolidation or merger or the effective
date of dissolution following any such transfer, as the case may be, and shall be binding upon the issuer of any Other Securities, including,
in the case of any such transfer, the person acquiring all or substantially all of the properties or assets of the Company, whether or
not such person shall have expressly assumed the terms of this Warrant as provided in Section 5 hereof.

 

4. Registration Rights.
The Holder of this Warrant shall have such registration rights for the Warrant Shares as are contained in the Purchase Agreement, if any.

 

5. Extraordinary Events
Regarding Common Stock. In the event that the Company shall (a) issue additional shares of Common Stock as a dividend or other distribution
on outstanding Common Stock, (b) subdivide its outstanding shares of Common Stock, or (c) combine its outstanding shares of the Common
Stock into a smaller number of shares of Common Stock, then, in each such event, the Purchase Price shall, simultaneously with the happening
of such event, be adjusted by multiplying the then Purchase Price by a fraction, the numerator of which shall be the number of shares
of Common Stock outstanding immediately prior to such event and the denominator of which shall be the number of shares of Common Stock
outstanding immediately after such event, and the product so obtained shall thereafter be the Purchase Price then in effect. The Purchase
Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described in this Section
5. The number of shares of Common Stock that the Holder of this Warrant shall thereafter, on the exercise hereof, be entitled to receive
shall be adjusted to a number determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions
of this Section 5) be issuable on such exercise by a fraction of which (a) the numerator is the Purchase Price that would otherwise
(but for the provisions of this Section 5) be in effect, and (b) the denominator is the Purchase Price in effect on the date of
such exercise.

 

6. Certificate as to Adjustments.
In each case of any adjustment or readjustment in the shares of Common Stock issuable on the exercise of the Warrants or in the Purchase
Price, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment
or readjustment in accordance with the terms of the Warrant and prepare a certificate setting forth such adjustment or readjustment and
showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the consideration received
or receivable by the Company for any additional shares of Common Stock issued or sold or deemed to have been issued or sold, (b) the number
of shares of Common Stock outstanding or deemed to be outstanding, and (c) the Purchase Price and the number of shares of Common Stock
to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted
as provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder. Holder will be entitled to
the benefit of the adjustment regardless of the giving of such notice. The timely giving of such notice to Holder is a material obligation
of the Company.

  

7. Reservation of Stock,
etc. Issuable on Exercise of Warrant; Financial Statements. The Company will at all times reserve and keep available, solely for issuance
and delivery on the exercise of the Warrants, all shares of Common Stock (or Other Securities) from time to time issuable on the exercise
of the Warrant. This Warrant entitles the Holder hereof, upon written request, to receive copies of all financial and other information
distributed or required to be distributed to the holders of the Company’s Common Stock.

 

    4

    

    

 

8. Assignment; Exchange
of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred
by any registered holder hereof (a “Transferor”). On the surrender for exchange of this Warrant, with the Transferor’s
endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”) and together with an
opinion of counsel reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance with applicable securities
laws, the Company will issue and deliver to or on the order of the Transferor thereof a new Warrant or Warrants of like tenor, in the
name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a “Transferee”),
calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the
Warrant so surrendered by the Transferor.

 

9. Replacement of Warrant.
On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the
case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory
in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at
its expense, twice only, will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

10. Maximum Exercise.
The Holder shall not be entitled to exercise this Warrant on an exercise date, in connection with that number of shares of Common Stock
which would be in excess of the sum of (i) the number of shares of Common Stock beneficially owned by the Holder and its Affiliates on
an exercise date, and (ii) the number of shares of Common Stock issuable upon the exercise of this Warrant with respect to which the determination
of this limitation is being made on an exercise date, which would result in beneficial ownership by the Holder and its Affiliates of more
than 4.99% of the outstanding shares of Common Stock on such date. For the purposes of the immediately preceding sentence, beneficial
ownership shall be determined in accordance with Section 13(d) of the 1934 Act and Rule 13d-3 thereunder. Subject to the foregoing, the
Holder shall not be limited to aggregate exercises which would result in the issuance of more than 4.99%. The Holder may allocate which
of the equity of the Company deemed beneficially owned by the Holder shall be included in the 4.99% amount described above and which shall
be allocated to the excess above 4.99%. The restriction described in this paragraph may be waived, in whole or in part, upon sixty-one
(61) days’ prior notice from the Holder to the Company to increase such percentage.

  

11. Transfer on the Company’s
Books. Until this Warrant is transferred on the books of the Company, the Company may treat the registered holder hereof as the absolute
owner hereof for all purposes, notwithstanding any notice to the contrary.

 

    5

    

    

 

12. Notices. All notices,
demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise
specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage
prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile
addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or
other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile,
with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on
a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if
delivered other than on a business day during normal business hours where such notice is to be received), or (b) on the second business
day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such
mailing, whichever shall first occur. The addresses for such communications shall be: (i) if to the Company, to Brain Scientific, Inc.,
6700 Professional Parkway, Lakewood Ranch, Florida, Attn: Bonnie-Jeanne Gerety, with a copy by fax only to (which shall not constitute
notice) Lucosky Brookman LLP, 101 Wood Avenue South, 5th Floor, Iselin, NJ 08830, Attn: Lawrence Metelitsa, Esq., facsimile: (732) 395-4401,
and (ii) if to the Holder, to the address and facsimile number listed on the first paragraph of this Warrant.

 

13. Governing Law; Jurisdiction
Etc. This Warrant and the terms and conditions set forth herein, shall be governed by and construed solely and exclusively in accordance
with the internal laws of the State of New York without regard to the conflicts of laws principles thereof. The parties hereto hereby
expressly and irrevocably agree that any suit or proceeding arising directly and/or indirectly pursuant to or under this Warrant shall
be brought solely in a federal or state court located in the City, County and State of New York. By its execution hereof, the parties
hereto covenant and irrevocably submit to the in personam jurisdiction of the federal and state courts located in the City, County and
State of New York and agree that any process in any such action may be served upon any of them personally, or by certified mail or registered
mail upon them or their agent, return receipt requested, with the same full force and effect as if personally served upon them in New
York, New York. The parties hereto expressly and irrevocably waive any claim that any such jurisdiction is not a convenient forum for
any such suit or proceeding and any defense or lack of in personam jurisdiction with respect thereto. In the event of any such action
or proceeding, the party prevailing therein shall be entitled to payment from the other parties hereto of all of its reasonable counsel
fees and disbursements.

 

14. WAIVER OF JURY TRIAL.
THE PAYEE AND THE COMPANY EACH HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE AND/OR THE TRANSACTIONS CONTEMPLATED HEREUNDER.

 

[-Signature Page Follows-]

 

    6

    

    

 

IN WITNESS WHEREOF, the Company has executed this
Warrant as of the date first written above.

 

	 	BRAIN SCIENTIFIC, INC.
	 	 
	 	By:	             
	 	Name: 	 
	 	Title: 	 

 

ACCEPTED AND AGREED TO BY HOLDER 

ON THE DATE FIRST WRITTEN ABOVE

 

	 	 
	Print Name of Holder	 
	 	 
	 	 
	Signature of Holder	 

 

    7

    

    

 

Exhibit A

 

FORM OF EXERCISE

(to be signed only on exercise of Warrant)

 

TO: BRAIN SCIENTIFIC, INC.

 

The undersigned, pursuant to the provisions set
forth in the attached Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

 

___ ________ shares of the Common Stock covered
by such Warrant; or

 

	___	the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth in Section 2 of the Warrant.

 

The undersigned herewith makes payment of the
full purchase price for such shares at the price per share provided for in such Warrant, which is $______. Such payment takes the form
of (check applicable box or boxes):

 

___ $__________ in lawful money of the United States; and/or

 

	___	the cancellation of such portion of the attached Warrant as is exercisable for a total of _______ shares of Common Stock; and/or

 

	___	the cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 2 of the Warrant, to exercise this Warrant with respect to the maximum number of shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth in Section 2.

 

After application of the cashless exercise feature
as described above, _____________ shares of Common Stock are required to be delivered pursuant to the instructions below.

 

The undersigned requests that the certificates
for such shares be issued in the name of, and delivered to __________________________________________, whose address is ___________________________.
_______________________________________________________________________________________________.

 

The undersigned represents and warrants that all
offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant to registration
of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant to an exemption from
registration under the Securities Act.

 

    8

    

    

 

	Dated:___________________	 	 
	 	 	
    (Signature must conform to name of holder as

    specified on the face of the Warrant)

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	(Address)

 

    9

    

    

 

Exhibit B

 

FORM OF TRANSFEROR ENDORSEMENT

(To be signed only on transfer of Warrant)

 

For value received, the undersigned
hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the right represented
by the within Warrant to purchase the percentage and number of shares of Common Stock of BRAIN SCIENTIFIC, INC. to which the within Warrant
relates specified under the headings “Percentage Transferred” and “Number Transferred,” respectively, opposite
the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on the books of BRAIN SCIENTIFIC,
INC., with full power of substitution in the premises.

 

	Transferees	 	Percentage Transferred	 	Number Transferred
	 	 	 	 	 

 

	Dated: __________________, _______	 	 
	 	 	
    (Signature must conform to name of holder as specified

    on the face of the warrant)

	 	 	 
	Signed in the presence of: 	 	 
	 	 	 
	 	 	 
	(Name)	 	 
	 	 	(address)
	 	 	 
	ACCEPTED AND AGREED:	 	 
	[TRANSFEREE]	 	 
	 	 	(address)
	 	 	 
	 	 	 
	(Name)	 	 

 

10Exhibit 10.1

 

ASSIGNMENT AND ASSUMPTION AGREEMENT

 

ASSIGNMENT AND ASSUMPTION AGREEMENT, dated
as of October 1, 2021, by and between Brain Scientific Inc., a Nevada corporation (“Assignor”), and MemoryMD, Inc., a Delaware
corporation (“Assignee”).

 

INTRODUCTION

 

WHEREAS, the Assignor contemplates
entering into a business combination on the date hereof, pursuant to which, among other things, Piezo Motion Corp., a Delaware corporation,
(“Piezo”) will merge with a newly-formed wholly-owned subsidiary of the Assignor with Piezo as the surviving corporation (the
“Business Combination”);

 

WHEREAS, in preparation for
the transactions contemplated by the Business Combination, the Assignor is required to contribute and assign any and all rights, title,
and interest to all assets and liabilities, to the extent assignable, which pertain to the operations of Assignor, in effect or in existence
as of immediately prior to the consummation of the Exchange (collectively, the “Assets and Liabilities”); and

 

WHEREAS, Assignee wishes to
irrevocably accept the contribution and assignment of the Assets and Liabilities, on the terms and subject to the conditions hereinafter
set forth.

 

NOW, THEREFORE, in consideration
of the mutual promises, warranties and covenants set forth herein, Assignee and Assignor hereby agree as follows:

 

1.
Assignor hereby assigns, transfers, contributes and conveys to Assignee, and its successors and assigns, all of the Assets and Liabilities
and all of the rights of Assignor pursuant thereto and in connection therewith, and Assignee hereby irrevocably accepts and assumes such
assignment, transfer, contribution and conveyance, and agrees to perform all of Assignor’s obligations and to satisfy each liability
thereof.

 

2.
Assignor and Assignee each hereby covenants that it will, whenever and as reasonably requested by the other, do, execute, acknowledge
and deliver any and all such other and further acts, deeds, assignments, transfers, conveyances, confirmations, powers of attorney and
any instruments of further assurance, approvals and consents as the other may reasonably require in order to complete, insure and perfect
the transfer, conveyance, contribution and assignment to Assignee of all the right, title and interest of the Company in and to the Assets
and Liabilities hereby assigned, transferred, contributed and conveyed, or intended so to be. Assignee hereby covenants that it will,
whenever and as reasonably requested by Assignor, do, execute, acknowledge and deliver any and all such other and further documents, acts
and deeds as shall be required in connection with the assumption of liabilities and obligations of Assignor contemplated by Section 1
hereof.

 

3.
Assignor’s interest in the Assets and Liabilities is being acquired by the Assignee on an AS IS WHERE IS basis and Assignor makes
no representations thereto or any other matter.

 

4.
The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective successors
and assigns.

 

5.
This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become
effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood
that all Parties need not sign the same counterpart. Facsimile or .pdf execution and delivery of this Agreement is legal, valid and binding
execution and delivery for all purposes. This Agreement shall be governed in all respects, including validity, interpretation and effect,
by the internal laws of the State of New York, without regard to the conflicts of law principles thereof.

 

6.
This Agreement may not be amended except by an instrument in writing signed by each of the parties hereto. This Agreement constitutes
the entire agreement of the parties with respect to the subject matter hereof and supersedes in its entirety any other agreement relating
to or granting any rights with respect to the subject matter hereof.

 

[Remainder of Page Intentionally Left Blank;
Signature Page Follows]

 

     

     

    

 

IN WITNESS WHEREOF,
the parties have duly executed this Assignment and Assumption Agreement as of the date first written above.

 

	 	BRAIN SCIENTIFIC INC.
	 	 	 
	 	By:	/s/ Boris Goldstein
	 	Name:	Boris Goldstein
	 	Title:	Chairman of the Board and Executive Vice President

 

	 	MEMORYMD, INC.
	 	 	 
	 	By:	/s/ Boris Goldstein
	 	Name:	Boris Goldstein
	 	Title:	Executive Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]